ADI 270
Alternative Names: ADI-270; CD70 CAR-T cell therapy - Adicet Bio; CD70-CAR-T-cells - Adicet BioLatest Information Update: 21 Aug 2024
At a glance
- Originator Adicet Bio
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Haematological malignancies; Renal cell carcinoma; Solid tumours
Most Recent Events
- 13 Aug 2024 Adicet Bio plans a phase I trial in Renal cell carcinoma (Second-line therapy or greater) (parenteral) in the fourth quarter of 2024
- 08 Jul 2024 ADI 270 receives Fast Track designation for Renal cell carcinoma [Parenteral] in USA
- 24 Jun 2024 US FDA approves IND application for ADI 270 in Renal cell carcinoma